If you need more lookups,
subscriptions start at $34 USD/month.
Anne Brindley Location
Lyndhurst, GB
Anne Brindley Work
Managing Director UK and Head of CMC @ (August 2021 - Present)
Chief Development Officer (part-time) @ Senari (April 2020 - Present)
Director and Consultant @ Altiba Ltd (November 2020 - Present)
Chief Executive Officer @ (December 2020 - January 2022)
CEO @ AuroScience Pty Ltd (December 2018 - February 2020)
CEO @ Advent Pharmaceuticals Pty Ltd. (March 2017 - December 2018)
VP and Managing Director @ Respivert (July 2013 - February 2017)
Head of Inhalation Product Development @ Respivert (October 2011 - June 2013)
Executive VP Pharmaceutical Development and Project Management @ (November 2009 - October 2011)
Director @ (January 1996 - November 2009)
Senior Scientist @ (November 1992 - December 1995)
Scientist @ (September 1987 - November 1989)
Anne Brindley Education
University of Nottingham
Ph.D (Drug delivery)
1989-1992
University of Bath
B.Pharmacy (Pharmacy)
1984-1987
Anne Brindley Skills
Drug Development
Product Development
Pharmaceutical Industry
Formulation
Technology Transfer
Clinical Development
Pharmaceutics
Regulatory Affairs
Oncology
Leadership
Project Management
GMP
Research and Development (R&D)
Outsourcing
JavaScript
Strategy
Molecular Biology
Research and Development R&d
Research and Development
Anne Brindley Summary
Anne Brindley, based in Lyndhurst, GB, is currently a Managing Director UK and Head of CMC at Pulmocide. Anne Brindley brings experience from previous roles at Senari, Altiba Ltd, Nuformix Plc and AuroScience Pty Ltd. Anne Brindley holds a 1989 - 1992 Ph.D in Drug delivery @ University of Nottingham. With a robust skill set that includes Drug Development, Product Development, Pharmaceutical Industry, Formulation, Technology Transfer and more. Anne Brindley has 2 emails on RocketReach.
Looking for a different Anne Brindley?
Find contact details for 700 million professionals.